Skip to main content
. 2021 Oct 12;31(5):364–374. doi: 10.1089/nat.2021.0002

FIG. 5.

FIG. 5.

Silencing of survivin suppressed tumor cell growth and sensitized cisplatin cytotoxicity in NSCLC Cells. (A) IncuCyte cell proliferation assay on both H596 and H1568 NSCLC cell lines posttreating with EGFRApt/Exo/siSurvivin, EGFRApt/Exo/siCtr, Exo/siSurvivin, and TES buffer in 50 nM of siRNA concentration. n = 3, error bar ± SEM. (B) Cell apoptosis evaluation by Annexin V-positive cells using flow cytometry on both H596 and H1568 NSCLC cell lines posttreating with EGFRApt/Exo/siSurvivin, EGFRApt/Exo/siCtr, Exo/siSurvivin, and TES buffer in 50 nM of siRNA concentration for 48 h followed by 24 h treatment with 5 μM cisplatin, n = 3, *P < 0.05, **P < 0.01, error bar ± SD. Original data and gating refer to Supplementary Fig. S4. (C) Cisplatin-induced apoptosis marker evaluation by western blot on both H596 and H1568 NSCLC cell lines posttreating with EGFRApt/Exo/siSurvivin, EGFRApt/Exo/siCtr,/Exo/siSurvivin, and TES buffer in 50 nM of siRNA concentration for 48 h followed by 24 h treatment with or without 5 μM cisplatin. SD, standard deviation; SEM, standard error of the mean.